<SEC-DOCUMENT>0001193125-21-097377.txt : 20210329
<SEC-HEADER>0001193125-21-097377.hdr.sgml : 20210329
<ACCEPTANCE-DATETIME>20210329060915
ACCESSION NUMBER:		0001193125-21-097377
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210329
FILED AS OF DATE:		20210329
DATE AS OF CHANGE:		20210329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		21779365

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d167795d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of March, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 29 March 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g167795g45f49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29&nbsp;March
2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA LICENSES RIGHTS TO PAXALISIB IN GREATER CHINA TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIMCERE, A LEADING CHINESE PHARMACEUTICAL COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney,</B><B> 29 March 2021</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to
announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere, &#20808;&#22768;&#33647;&#19994;) (HKSE: 2096) to develop and commercialise Kazia&#146;s investigational new drug, paxalisib, in Greater China.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Simcere will assume responsibility for the development, registration, and commercialisation of paxalisib in
Greater China - a territory which includes Mainland China, Hong Kong, Macau, and Taiwan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kazia retains rights to the development and commercialisation of paxalisib in all other territories and will
continue to drive forward the GBM AGILE pivotal study as planned, including in China. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the terms of the agreement, Kazia will receive an upfront payment of US$ 11 million (~AU$ 14.2 million),
comprising US$ 7 million in cash and a US$ 4 million equity investment, priced at a 20% premium to recent trading. Kazia will also receive contingent milestone payments of up to US$ 281 million (~AU$ 362 million) for glioblastoma, with further
milestones payable for indications beyond glioblastoma. Simcere will additionally pay to Kazia mid-teen percentage royalties on commercial sales. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Transaction proceeds will be applied directly to the further development of paxalisib. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Simcere is one of China&#146;s leading pharmaceutical companies, with over 40 marketed products and an extensive
development pipeline. It was incorporated in 1995 and is listed on the Hong Kong Stock Exchange (HKSE: 2096). Simcere&#146;s primary areas of strategic focus are in oncology, central nervous system disease, and autoimmune disease.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paxalisib is currently the subject of six additional studies in other forms of brain cancer beyond glioblastoma.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner, commented, &#147;China is one of the world&#146;s largest pharmaceutical
markets, with specific requirements and opportunities for innovative oncology products. We are delighted to partner with Simcere to secure the commercial success of paxalisib in this critical territory. Simcere&#146;s track record of success is
unrivalled, and they bring to paxalisib first-class capabilities in clinical development, regulatory affairs, and commercialisation. We look forward to working closely with our new partners to make paxalisib available for Chinese patients as swiftly
as possible.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Renhong Tang, Senior Vice President at Simcere, added, &#147;we are tremendously excited by the potential for paxalisib to make a
difference in this very challenging disease. The need for new therapies in brain cancer is significant in China, and we share Kazia&#146;s commitment to bringing forward new treatment options for patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia has been advised in this transaction by Janette Dixon at JustPartnering and by Dragon Financial Partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Simcere Pharmaceutical Group </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simcere Pharmaceutical
Group is rapidly transitioning to an innovation and R&amp;D-driven pharmaceutical company, with a mission of &#147;providing today&#146;s patients with medicines of the future.&#148; It has established a national key laboratory of translational
medicine and innovative pharmaceuticals. Simcere focuses on oncology, central nervous system disease and autoimmune disease therapeutic areas, with a diversified product portfolio and industry-leading capabilities. Its vigorous in-house R&amp;D
efforts and extensive R&amp;D collaborations have made it a strategic cooperation partner with world leading pharmaceutical companies and biotechnology companies, in an effort to bring more global life science breakthroughs to China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.simcere.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Issuance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the transaction,
Simcere will make a US$ 4 million (~AU$ 5.2 million) equity investment in Kazia, priced at a 20% premium to recent trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to Kazia&#146;s
2016 purchase of Glioblast Pty Ltd, this transaction satisfies the conditions for Milestone 4 of that agreement and will therefore result in the issuance of escrowed ordinary shares to Glioblast shareholders, under terms previously disclosed by
Kazia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paxalisib </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib is a brain-penetrant
inhibitor of the PI3K / Akt / mTOR pathway, which is disordered in the vast majority of patients with glioblastoma, the most common and most aggressive form of primary brain cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a phase II study in patients with newly diagnosed glioblastoma with unmethylated MGMT promotor status,
paxalisib has shown highly encouraging signals of clinical efficacy. In January 2021, patient recruitment commenced for paxalisib in the GBM AGILE platform study, which is expected to serve as the basis for registration in key territories. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Conference Call </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is pleased to invite
investors to attend a conference call to further discuss the partnership with Simcere. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The call will be held on Tuesday 30 March 2021 at 8:00am, Sydney
time (AEDT), which is 5:00pm on 29 March in New York (ET) and 2:00pm on 29 March in San Francisco (PT). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participants will need to <B>pre-register</B> for
the call via the following link: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://s1.c-conf.com/diamondpass/10013168-83hs6e.html</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Click the &#145;Register Now&#146; button and follow the prompts to complete pre-registration. You will receive a calendar invite with dial in numbers,
passcode and PIN to join the conference call. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gabriella Hold </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>gabriella.hold@irdepartment.com.au</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +61 411 364 382
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (ASX: KZA, NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a
brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced
recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in other forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q&amp;A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why has Kazia chosen to partner Greater China rights to paxalisib at this stage? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">China has unique regulatory and market access requirements, which require active engagement some time before a commercial launch. Partnering with a first-class
Chinese pharmaceutical company at this stage helps to ensure that the launch of paxalisib is not delayed in China, and that it is optimised for commercial success. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the proceeds of this transaction will allow Kazia to substantially fund the remaining development of the paxalisib program, and to undertake
additional exploratory clinical studies as appropriate. In effect, the paxalisib program has become partially self-sustaining in economic terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How
does this transaction affect the likelihood of a global (ex-China) partnership for paxalisib? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia retains unfettered rights to all territories
outside Greater China and may license all or part of these territories at its absolute discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#145;Global&#146; licensing deals with large
pharmaceutical companies often exclude particular territories, for example in the licensor&#146;s home country, and so the exclusion of Greater China rights for paxalisib is highly unlikely to constrain such a transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia will continue to evaluate all options and will seek to put in place additional commercial arrangements at a time and in a manner that ensures the most
effective product launch and which optimizes value for Kazia&#146;s shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do the deal terms of this transaction compare to Kazia&#146;s
expectations in other territories? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">China accounts for 8-10% of the global pharmaceutical market. The remaining ~90% of the commercial rights for
paxalisib remain available to Kazia for future transactions. Given that territories such as the United States are typically associated with higher profit margins, and that any transaction for such territories is likely to take place in the context
of a more substantial body of clinical data for the asset, Kazia expects to realise proportionally superior value in any such partnership. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do the
terms of this transaction compare to similar licensing deals in China? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licensing terms in this transaction are highly consistent with previous
transactions between multinational companies and Chinese companies in this disease area. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2018, Novocure (St Helier, Jersey) and Zai Lab
(Shanghai, China) announced a strategic collaboration and license agreement for Novocure&#146;s Tumor Treating Fields (TTF) medical device, marketed as Optune<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Optune was previously approved
by FDA for glioblastoma in 2011. The transaction included a US$ 15 million upfront payment, undisclosed milestones, and a royalty rate from 10% to mid-teens.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Novocure press release &#150; 12 September 2018 </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2019, Mimivax LLC (Buffalo, NY) and Fosun Pharma Industrial (Shangahi, China) entered into a
licensing agreement for Mimivax&#146;s SurVaxM product, following completion of a phase II clinical trial in glioblastoma. The transaction included a US$ 10 million upfront payment and up to $138 million in contingent milestones. Any royalties were
undisclosed.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the size of the Chinese pharmaceutical market? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pharmaceutical market in the People&#146;s Republic of China was estimated to be worth approximately US$ 130 billion in 2018.<SUP
STYLE="font-size:85%; vertical-align:top">3</SUP> China accounts for around 8%-10% of total global pharmaceutical expenditure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How common is
glioblastoma in China? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glioblastoma is not believed to demonstrate substantial ethnic or geographic differences in incidence, and so Chinese patients
would be expected to develop glioblastoma at about the same rate as patients in other countries, when matched for age and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are
estimated to be around 25,000 new cases of glioblastoma in China each year, which is approximately twice the annual number of cases in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How is glioblastoma treated in China, compared to Western countries? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients in China are treated in very similar fashion to those in the US and other Western countries. The Stupp Regimen, comprising surgery, chemoradiotherapy,
and up to six months of maintenance treatment with temozolomide, is the standard of care in China, as it is elsewhere around the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Temozolomide is
widely available as a generic medicine in China. In addition, Avastin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (bevacizumab) was approved in China for recurrent glioblastoma in September 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>At what level does Kazia anticipate paxalisib to be priced in China? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is not able to provide indicative pricing for paxalisib in China at this stage. In general, novel medicines are typically priced lower in China than in
the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Which other companies were considered as partners? Why did Kazia decide to partner with Simcere? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia conducted a broad-based process which involved outreach to more than two dozen companies in China. Short-listed candidates were invited to submit
proposed deal terms, and the final decision was based on a combination of value, capability, and commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simcere was selected as the partner of
choice because of its first-class R&amp;D capabilities, its extensive commercial infrastructure, its track record of success, its entrepreneurial culture, and the shared values between the two companies. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Mimivax press release &#150; 18 November 2019 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">DaXue Consulting </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia licensed paxalisib from Genentech in 2016. How do the deal terms of this transaction compare to
Kazia&#146;s financial commitments to Genentech? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia&#146;s potential receipts from Simcere substantially exceed its obligations to Genentech in
respect of the licensed territories. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The GBM AGILE study is expected to commence recruitment in China during CY2021. What are the implications of this
transaction for paxalisib&#146;s inclusion in this study? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia and Simcere expect the GBM AGILE study to proceed as planned in China, and to provide
the basis for a product approval. The companies will collaborate closely to consult with the Chinese regulatory agency, the National Medical Products Administration (NMPA), over the coming months. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g167795g45f49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g167795g45f49.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( (X#- ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\)P*3<*24XC;Z5^:_Q<_X.2O
M_P (OC%XR\&W'PQ\:7UUX+\0:CX>GNH;VT2*YELKJ6V>1 S;@K-$6 /.".^:
MUI49U':"N9U*T*:O-V/TIW"C<*_+?_B*,\!?]$G\=_\ @PLO_BZ/^(HOP#_T
M2GQY_P"#"Q_^+K7ZCB/Y&<_UZA_.C]2-PHW"ORW_ .(HOP#_ -$I\>?^!]C_
M /%T?\11G@+_ *)/X[_\&%E_\71]1Q'\C#Z]0_G1^I&X4;A7Y;_\11G@(_\
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M1G@'_HE'CS_P86/_ ,71]1Q'\C#Z]0_G7XGZD;A1N%?EO_Q%%^ ?^B4^//\
MP/L?_BZ/^(HSP"/^:4^//_!A8_\ Q='U'$?R,/KU#^='ZD;A1N%?EO\ \11G
M@+_HD_CO_P &%E_\71_Q%%^ ?^B4^//_  86/_Q='U'$?R,/KU#^=?B?J1N%
M&X5^6_\ Q%%^ ?\ HE/CS_P86/\ \71_Q%&> O\ HD_CO_P867_Q='U'$?R,
M/KU#^=?B?J1N%&X5^6__ !%&> 3_ ,TH\>?^#"Q_^+H_XBB_ /\ T2GQY_X'
MV/\ \71]1Q'\C']>H?SH_4C<*-PK\M_^(HSP$/\ FE'CS_P86/\ \71_Q%&>
M O\ HD_CO_P867_Q='U'$?R,7UZA_.OQ/U(W"C<*_+?_ (BB_ /_ $2GQY_X
M'V/_ ,71_P 11?@'_HE/CS_P86/_ ,73^HXC^1C^O4/YU^)^I&X4;A7Y;_\
M$49X"_Z)/X[_ /!A9?\ Q='_ !%&> 3_ ,TH\>?^#"Q_^+I?4<1_(Q?7J'\Z
M_$_4C<*-PK\M_P#B*+\ _P#1*?'G_@?8_P#Q='_$49X"_P"B3^.__!A9?_%T
M?4<1_(P^O4/YU^)^I&X4;A7Y;_\ $49X"_Z)/X[_ /!A9?\ Q='_ !%%^ ?^
MB4^//_ ^Q_\ BZ/J.(_D8?7J'\Z_$_4C<*-PK\M_^(HOP#_T2GQY_P"#"Q_^
M+H_XBC/ 7_1)_'?_ (,++_XNCZCB/Y&'UZA_.OQ/U(W"C<*_+?\ XBB_ /\
MT2GQY_X,+'_XNC_B*+\ _P#1*?'G_@?8_P#Q='U'$?R,/KU#^='ZD;A1N%?E
MO_Q%&> O^B3^._\ P867_P 71_Q%&> O^B4>._\ P86/_P 71]1Q'\C#Z]0_
MG7XGZD;A1N%?EO\ \11?@'_HE/CS_P #['_XNC_B*,\!#_FE'CS_ ,&%C_\
M%T?4<1_(P^O4/YT?J1N%&X5^6_\ Q%&> O\ HD_CO_P867_Q='_$47X!_P"B
M4^//_!A8_P#Q='U'$?R,/KU#^=?B?J1N%&X5^6__ !%%^ ?^B4^//_ ^Q_\
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MC/ 7_1*/'G_@PL?_ (NCZCB/Y&'UZA_.OQ/U(W"C<*_+?_B*+\ _]$I\>?\
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MP%_T2?QW_P"#"R_^+H^HXC^1B^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X\_\
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M\_\ !A8__%T?\11?@'_HE/CS_P #['_XNCZCB/Y&/Z]0_G1^I&X4;A7Y;_\
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M-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\
M?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_
MW:,?[M'_ 'S1_P!\T &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,
M?[M'_?-'_?- !C_=HQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?
M]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T
M?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_W:,?[M'_ 'S1_P!\
MT &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,?[M'_?-'_?- !C_=
MHQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_
MNT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_W
MS1_WS0 8_P!VC'^[1_WS1_WS0 ZV'^D1_=^]VK^E3_@CU_RBN_9[_P"Q!TC_
M -)8Z_FKM_\ CXC^[]ZOZ5/^"/7_ "BN_9[_ .Q!TC_TECKQLZ_AQ]?T1ZN3
M_'+T_5GTA1117SA[XV3_ %;?2OY8?VSSC]M[X[?=_P"2F>*.O_89O*_J>D_U
M;?2OY8?VSSC]M[X[<_\ -3/%'_IYO*]C)?XK]/U/'SC^''U/.=W^[1N_W:-W
M^T/RHW?[0_*OI#PPW?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@!UL?](C^[][M7]*G_  1Z_P"45W[/?_8@
MZ1_Z2QU_-7;G-Q'R/O5_2I_P1Z_Y17?L]_\ 8@Z1_P"DL=>-G7\./K^B/6RC
MXY>GZL^D****^</>&R?ZMOI7\L/[9YQ^V]\=N?\ FIGBCM_U&;NOZGI/]6WT
MK^6']L\X_;>^.W/_ #4SQ1V_ZC-Y7LY+_%?I^IX^<?PX^IYSN_VOTHW?[7Z4
M;O\ :_2C=_M?I7T9X8;O]K]*-W^U^E&[_:_2C=_M?I0 ;O\ :_2C=_M?I06]
M_P!*]NT[]A_4-0_X)XZA^T"OB73_ "K#4VB_X1EK<&ZETX:A_9C:CYBR;MBW
M@*&(1Y*JS;^1B)5(QMS/?0J,7+X?4\1W?[7Z4;O]K]*]R^*?[%EI\&OV:M$\
M;ZM\1]"7Q5KWA#2O'FG^$'LGBN-2TF]E,:+973LL5W?1 ;Y;95QM/$FTAJT_
MVC/^">M_\ /!"^(H?%2^)M)\4:WI.C_#633]+8R_$>*^LH[QKNWA\TR1Q0K<
M16^%$IDG94#*<9S6*I-V3-/J]1=#YZW?[7Z4;N>M>H?LY_LJ:]^TSI'Q(_X1
M\S2>(OA_9:;-;:.MH9)-9NK[41816V[<OV?#X=G<-M (*CDKW?PT_8F\#_$3
M]KC5/@Y;_&2:;7H=;A\/:+=Z=X(N=2A\077E.U\%\NX BAM&20&9CB1$,J;5
MXISQ$(WOTW%&A.232WV/G3=S][]*-W^U^E>__L^_L&_\-*ZG\7E\.^.-/DT_
MX=S7-GX9NDTYYQ\0[I(=1N;>WM,2 1F6TL#,&;?@2J<$Y)\;^&G@L?$W1/&5
MY#??91X2\+-XF4&$O]L OK"U\GJ-G_'[OW8/,6W&&R"->#Z[?KL'L)JUUO\
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M?I1N_P!K]*-W^U^E&[_:_2@ W?[7Z4;O]K]*-W^U^E&[_:_2@ W?[7Z4;O\
M:_2C=_M?I1N_VOTH -W^U^E&[_:_2C=_M?I1N_VOTH -W^U^E&[_ &OTHW?[
M7Z4;O]K]* #=_M?I1N_VOTHW?[7Z4;O]K]* #=_M?I1N_P!K]*-W^U^E&[_:
M_2@ W?[7Z4;O]K]*-W^U^E&[_:_2@ W?[7Z4;O\ :_2C=_M?I2Q*\\RQQJTD
MCG"HJ%F<^@ ')]AS1J]$ TOCO^E:/A/PIJOCWQ';Z/HFGWFK:I>$B&UM8_,E
MDP,L0HYV@<ECP/6O9_V"?A9X/^(WQ1UVQ\90QW%YI]DDFGZ7=R&$3N9 ')C^
M5G95_A]#G'%;4OQ'\(_L9?MH:U)X?M/[8\+S:8+*[@M9_.ET^23YG2%V8API
M1#ACDAB-PKTJ.7WA"M5DHP<K/NO.Q\WBL_:KU<%A*;G5C#FC?2+?:YX+XA\
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M"VT'@MC )&2,C/0?\,]_$3_HG_CS_P )V]_^-5,IQ3LV-1;V.1W?[7Z4;O\
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M_+#^V?\ \GO?';[W_)3/%'_IYO*]C)?XK]/U/'SC^''U/.<^[?E1GW;\J/\
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MY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\ OJ@ S[M^5&?=ORH_[ZH_[ZH
M,^[?E1GW;\J/^^J/^^J #/NWY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\
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M;M2\;LNK^(U1OFM]*A?]W$3U7[1<*J\9W1PSCCJ/QI<_,WS-U)SLVY_#H*]
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M^*O!G@%=8C\3>)=0\'1>'[W7KFXFU"YC@L8M/749;=HFM-0FNKBXE2"'9&\
MM3MP6>2K\8M'^'OP\^-O[0VM:7X;.N> ?A'83W>DZ#_:TT4>IR1ZQIFCLSW2
MDRM"_P!HN)QA\D^2"2BE6Q=8_:Y^(FO^(O#.K7FO0S7_ (1UQ/$UA+_9=FOG
M:JD,,*7]T!$!>7(CMX5\VY\Q_P!V#G<23QWPW\;ZE\*-:FOM)_L^:2ZLSI]U
M!JNFVVK6E[;F6"?RI[>ZCDBF7SK>&3YT8AT# @@&M/83:_X/G_D3&I36Z_JW
M^9]$_'C]B[P_\.OAMXI70/L^J:]:WGBW4;,W>JR_VK::=HWB$:472V2,6]Q&
MEO%)-.TC)*SS*T.V*WFC;S+XY:%\.=)\+_#'Q5HMC=Z1H.N7>HG7+.WUA+ZX
MM[.UO8MJR2296WU;['.C2Q,OE1B>UD"%)3&F)??M)^.M4\ >(/#5UX@FNM-\
M43WMQJ,LMO"U_(U[<175XJ7>S[1#'/<012R112+&[H"5Y8&+X@?M >+/BAXR
MTG7]:NM*FU31=5DUV"2WT.PLXIM0DDBDFNYXH84CN)I6M[?S7F5S*L**^Y<@
MS1HU8VYF.I4I-OE1[GHGP=^%UK\9]0T?6-)\->%]>O\ PIH,]MX6\3^(]5M]
M.TC7[[58XVLI9[<"[,BZ=)#++&1)Y$K2;BJ197FO%W[,?A_2_P!E?Q7K4?V.
MU\5>"=,L]1U@C6HVOK/6&U^72[_2)M/+DK#;++:-'/L!?&\R2"=5CXBX_:X\
M=3_%K4/'"S^&;?Q%JZ!;^6#PKI4=M?.+Q;X7$MN+?R9+D7*1R_:60S9C7Y\#
M!Q=4^/GB[6_AE)X/N]56XT.XN3<W >RMS>71-W/>A);SR_M,D0NKF><1/*8Q
M+(6"Y"D'U>I=._:^H_;4M58]4^''AOX8>)-,^"]UXK\-Z'X5T[Q;K&OG5KD>
M([[R;W2M/TYH()KGS)7\@3ZO'<1EH0K%8BJCYAG7^'_[)EGXV\2_$K7+KPG+
M>>%[/P4;[PO'X4EU.ZT^;4+CP]<ZM878DN5%T84CM%+Q3A<S7T2;<*%'@UK\
M6/$5CK?@_4H+^.&]\!V":9HKK:0;+:W62>0H\939-O>YG,GFJ_F^:P?<"15Y
M?C[XRM_&%[KEIKD^FWE]I;Z(\6GQ16=G'8M9&P%O';QJL4:):XC38H*8# A_
MFJG1J+6+UU_/04:U-V4EV_+4XNU?SK:-O[R@\' J3'L?SIL4*P1*B)M6-0J@
M'H ,4['^S^M=GJ<@8]C^=&/8_G1C_9_6C'^S^M !CV/YT8]C^=&/]G]:,?[/
MZT &/8_G1CV/YT8_V?UHQ_L_K0 8]C^=&/8_G1C_ &?UHQ_L_K0 8]C^=&/8
M_G1C_9_6C'^S^M !CV/YT8]C^=&/]G]:,?[/ZT &/8_G1CV/YT8_V?UHQ_L_
MK0 8]C^=&/8_G1C_ &?UHQ_L_K0 8]C^=&/8_G1C_9_6C'^S^M !CV/YT8]C
M^=&/]G]:,?[/ZT &/8_G1CV/YT8_V?UHQ_L_K0 8]C^=&/8_G1C_ &?UHQ_L
M_K0 8]C^=&/8_G1C_9_6C'^S^M !CV/YT8]C^=&/]G]:,?[/ZT &/8_G1CV/
MYT8_V?UHQ_L_K0 8]C^=&/8_G1C_ &?UHQ_L_K0 8]C^=&/8_G1C_9_6C'^S
M^M !CV/YT8]C^=&/]G]:,?[/ZT &/8_G1CV/YT8_V?UHQ_L_K0 8]C^=&/8_
MG1C_ &?UHQ_L_K0 8]C^=&/8_G1C_9_6C'^S^M !CV/YT8]C^=&/]G]:,?[/
MZT &/8_G1CV/YT8_V?UHQ_L_K0 8]C^=&/8_G1C_ &?UHQ_L_K0 FSZ_G7JO
M[%WPQ\-_%OX[V>B^*&W:?#:S7-O9^;Y/VR<#A RX;U8A2&;&,\UY7C_9_6@!
ME92OR[>1['U'H1ZBML/4C3JQG-<R3O;N<N.PTL1AYT82<')-*2W5^JN>U?MT
M?![PU\(OC#I>F>$XY(9-0LVFO=-25Y_L<V]53&XLP\P$G:Q/*\8'%8_PW_:8
M;X??#1]!.B_:+FW,JVTXE54^<G<)%/)*DGZ]#C%=!^P=\9_"OP:^)NLWGBIF
MM6U.R6"TU(Q/-]D<.&8$C<Z[U!&X ^A.#BND;PAX1_;=_;8U3^R[R;2O#MOI
M"W5S+!%Y%QJTD/RL\2LN(PVY02P+;4+;<U>:Y'@\WIQY[>]--0O:S6S]-S'A
M7CG..$<145"4H\M%J59J,N:+M=6DG?I;S2Z'$_!_Q/\ #W1O@#-I^L6]I)J@
MCE$Z/$&N+M^1$T3[21\NT##+M.3WK+^'W[3EQX%^$L?AO^RX[BYMHGMX+D.-
M@20LQWI_$P+D9'!Q78?%S]C;3?!_[57@WP+I^NW2:3XP42K-=JDMU9*K%74X
M(1MV,H> <$8S6I^U/^S'X7_92UWP/XEL9M2UC29-;6&^TG4&22:X2+,IVD*B
ML"J%74\ LO/.*\67 =)^VGBDY1512:<M(R6W+Y*^Q]E1\=,53^I4LKY:,UAY
M4XN%-*4X.]^>]US7C=-6M+6VNOC_ , ?A]I7B;XS^$]!\527&GZ#JMPL<TDA
M:W^T)M^50QP<.<+N'][K7L'_  4+^!G@OX.3>&[CPW:0Z-K6I/)%>:?'.\IE
MM]A(G82,Q7# +Q@-OZ'%;'[>'[4G@/XW?"[3M&\.SW&KZ@U^E['-)926_P#9
MD0SO0L^#O8';L7*@<YXKY6^9R"<G@#!.>!TKZG$RHX:$\+"T[VM+MY'Y?EU/
M&YC5I9CB.:BH\R=)N\7VEK;5W=[KS5@5<#A=H] >!2X^OYT!<#[OZT8_V?UK
MQSZX[Z3PYX37]F63Q(-+UQ?$*ZPFA"9M20VOGR6]Q<"Z\KR<A52$)L#[CR=W
M0'KK?]E'3Y=9M9OM5K_8<W@?_A(FM_[6MEU,W:V,UQQ!@OY.]$XVG"9^;O7D
M/_"27W_"%OX>\Q?[)DU%=6,.Q=QN5AD@5]^-W$<L@VYQ\V<9 QI0_%/7H/$L
M>KK>1_;XM'&@(YMX]HLQ"\'E[=N,^7(XW8W<YSFNZ%>C:TX]O^">'6P6-LU1
MJ6NY/5MZ.UEY'9>%OACX?B_9BL?&5]:SW&KZ@^J19&OVNG;%MD@9?+MY$,ES
MS-RD;9/RCC-;OP^_9R\.^(/@;HWB#4/[4LVNM*U34=1UR+4K:*#2'M7,<+&T
M9?-G1W,:81^"X'4BO.=!^,OB#PY\/X_"]NVERZ/ ;AH4NM*M;J6!IU196CDE
MC9T8JBC*D$8!ZU!HGQ6U[P]ING6=K=1BTTO3;W1X(9((Y8VM+PDW$4BL")0Q
M.?G#8(!&,54*V'33E&^B^^ZO^%S&ME^.E%J$U%\[DM9?#[UEMO\ #W2MM+9]
M'\)/@'<?$?X(^(_$FZYMM5A4C0K.-6=;][:,7-\I8 C*0?*F?O/(N,UT/P-^
M OA7Q[\&K7Q!K4UY90WVL7UA<:RNKV]K;:3##:PS1RM!*I-QNDEV%8SNY'&>
M:X/P]\<?&'A*UT"WTO7]0L;;PS&8K&"*3$)!E>5C+']V=F9SN,H8L H/ K%U
M'Q1?ZIX8M]&DDC73;/4;G58(8X47R[BX6-)6! SM*11J$SM4*, 'FHC4P\5&
MT;V6M]F[IW_-&U3"8^ISQ=113DFK7NEK==-]'>_??9^E?#3X7>']1_9NL/&&
ML6=Q<:C?7MY;S0GQ';:3'$D,/F#8DJ,T\A_N)SC'&:S_ (;_  ;TWQ:OP12\
MFU R?$?7;S2]6$<N/W4,]E$OE!@2K8N'/S;OX<C'%87ACXW^(O"7@U?#UO)I
M=QHR3/<1VU]I5K>K#(XPS(98V*DCN#1X ^.?BKX7^&VTG1=3^S6?GM=0^9;Q
M326,S)Y;S6\CJ7@D9< O&5.% R,4>THOD5K66OK=?I<SE@\P3JRA)7<FXZM>
MZU)+2SM9M2TM\-C9^&WA;PAJ'PQ\=ZAK.E:[=WWA,K(AMM42W2XCFOH[.)=K
M0/@IN+ELG< %"CK4G@SX#0^.)_@OI5K>/9W7Q(>_@OY9,/#;B"[,0>)1CI&#
M\I."W85P.C:]>^'_  [K6E6<JPV7B&*"'4%\M2UPL,ZSQY8C((D4-D<FK,OC
M?5I+7P["MY)"OA)IWTAX0(Y;)IIA.Y5UPQ/F ,,DX[5'MJ=E>/3];_EH=-3!
MXKFDX5'\3MK>R]FTK7_Z>6=NQLZK<_#WQ!KNBPZ+:>)O#VEIJR6^IWM_/;WF
MZPW[&G\J.-"DRJ"S(2R@< DX!O?M"_#O3OA]XGTY=&TRZL]%U*VEFL;LZK!J
M=KJZ+-M6XMYHHXR!LP'C=0R,<8'>CXV^.OBCXA7VFW6J75C)<:5??VG!)!IM
MM;L]W\O[^3RXU\USMY+[@<G(.:H_$#XFZU\3[BR?5YK5H]-22.TM[2TBL[:W
M\U_,F98HE5 TDF'<XRS!3V%$JE-Q:2UTL[6%A\+B8SI.5K13YES-[]M%?Y[;
M(Y_'L?SHQ['\Z,?[/ZT8_P!G]:Y3V Q['\Z,>Q_.C'^S^M&/]G]: #'L?SHQ
M['\Z,?[/ZT8_V?UH ,>Q_.C'L?SHQ_L_K1C_ &?UH ,>Q_.C'L?SHQ_L_K1C
M_9_6@!UN/](CZ_>]:_I4_P""/7_**[]GO_L0=(_])8Z_FKMA_I$?^]7]*G_!
M'K_E%=^SW_V(.D?^DL=>-G7\./K^B/5R?XY>GZL^D****^</?&R?ZMOI7\L/
M[9XS^V]\=N/^:F>*/_3S>5_4])_JV^E?RP_MH?\ )[WQVX7_ )*9XHZ_]AF\
MKV<E_BOT_4\?./X<?4\YQ_L_K1C_ &?UHQ_LK1C_ &5KZ,\,,?[/ZT8_V?UH
MQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H ,?[/
MZT8_V?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_
MV5H ,?[/ZT8_V?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]
M:,?[*T8_V5H ,?[/ZT8_V?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^
MS^M&/]G]:,?[*T8_V5H ,?[/ZT8_V?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&
M/]E: #'^S^M&/]G]:,?[*T8_V5H ,?[/ZT8_V?UHQ_LK1C_96@ Q_L_K1C_9
M_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H ,?[/ZT8_V?UHQ_LK1C_96@ Q
M_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H ,?[/ZT8_V?UHQ_LK
M1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H ,?[/ZT8_
MV?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H
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MXJ_I4_X(]?\ **[]GO\ [$'2/_26.OYJ[8?Z1'POWNU?TJ?\$>O^45W[/?\
MV(.D?^DL=>-G7\./K^B/6RCXY>GZL^D****^</>&SAC"VW[V.*_'/X]_\&W?
MQ/\ BU^T)\1/&%C\0O =K8^,_%FK^(;:WN+>[::WBO+Z>Y2-RJXW*LH4XR,@
M\D5^QQ&10%Q6]#$5*+YJ;,:V'A55IH_$?_B%_P#BS_T4GX<_^ M[_P#$T?\
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M]_P#^S*';\6?B/\ \0P'Q8_Z*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M]_P#^S:';\6?B.?^#8#XL9_Y*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
M\37[<44?VIB>_P" ?V;0[?BS\1_^(8#XL_\ 12?AS_X"WO\ \30?^#7_ .+'
M_12OAS_X"WO_ ,37[<44?VIB>_X!_9M#M^+/Q'_XA@/BQ_T4KX<_^ U[_P#$
MT#_@V ^+'_12OAS_ . M[_\ $U^W%%']J8GO^ ?V;0[?BS\1_P#B%_\ BS_T
M4GX<_P#@+>__ !-'_$,!\6/^BE?#G_P&O?\ XFOVXHH_M3$]_P  _LVAV_%G
MXC_\0P'Q8_Z*5\.?_ :]_P#B:/\ B%_^+/\ T4GX<_\ @+>__$U^W%%']J8G
MO^ ?V;0[?BS\1S_P; ?%C_HI7PY_\!;W_P")H_XA@/BQ_P!%*^'/_@->_P#Q
M-?MQ11_:F)[_ (!_9M#M^+/Q''_!K_\ %C_HI7PY_P# 6]_^)H_XA@/BS_T4
MGX<_^ M[_P#$U^W%%']J8GO^ ?V90[?BS\1_^(8#XL?]%*^'/_@->_\ Q-'_
M !# ?%C_ **5\.?_  %O?_B:_;BBC^U,3W_ /[-H=OQ9^(__ !"__%G_ **3
M\.?_  %O?_B:#_P; ?%C/_)2OAS_ . M[_\ $U^W%%']J8GO^ ?V;0[?BS\1
M_P#B& ^+'_12OAS_ . U[_\ $T#_ (-?_BSC_DI/PY_\!;W_ .)K]N**/[4Q
M/?\  /[-H=OQ9^(Y_P"#7_XLX_Y*3\.?_ 6]_P#B:/\ B& ^+'_12OAS_P"
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8@8KGKXNK6_B,Z*.%ITM8(****YSH/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
